乳房切除术后的放射治疗:一个ASTRO/ASCO/SSO临床实践指南.
Rachel B Jimenez1, Yara Abdou2, Penny Anderson3
1Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Practical radiation oncology
|September 16, 2025
概括
乳腺切除术后的放射治疗 (PMRT) 建议用于大多数节点阳性乳腺癌患者和选择节点阴性病例. 更新的指南涵盖了前期手术或新辅助治疗后的PMRT的指示,体积,剂量和技术.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 乳腺癌治疗方法 乳腺癌治疗方法
背景情况:
- 乳腺切除术后的放射治疗 (PMRT) 是乳腺切除术后治疗乳腺癌的关键组成部分.
- 治疗PMRT的指示,技术和最佳使用已经发展,需要更新基于证据的指导方针.
研究的目的:
- 为乳腺癌治疗中使用乳腺切除术后放射治疗 (PMRT) 提供基于证据的建议.
- 在前期的手术和后期的neoadjuvant设置中更新PMRT指示的指导.
- 详细说明PMRT的适当目标体积,剂量和治疗技术.
主要方法:
- 一个由主要瘤学会召集的多学科工作组系统地审查了文献.
- 使用预定义的共识建设方法和证据分级系统,制定了建议.
- 关键问题涉及PMRT的指示,治疗量,剂量分数和技术.
主要成果:
- PMRT适用于大多数节点阳性乳腺癌患者的乳腺切除术后和选择节点阴性病例.
- 在局部晚期疾病或残留结节疾病的新辅助疗法后推使用PMRT.
- 关于目标体积,适度低分化偏好,基于CT的规划和针对特定患者子组的玻尿酸的使用,提供了具体的指导.
结论:
- 这些更新的,基于证据的建议旨在标准化和优化PMRT在乳腺癌管理中的临床应用.
- 这些指导方针提供了一个关于PMRT指示和输送技术的决策框架.
相关概念视频
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Standards of Care II
1.0K
Nurses bear specific legal responsibilities under several federal statutes, including:
1.0K


